Market news

Arcturus Therapeutics (ARCT) shares rose 6.3% in Thursday afternoon trading, a day after it reported

Arcturus Therapeutics (ARCT) surged over 6% after sharing positive Phase 2 interim data for its OTC deficiency drug, ARCT-810.

Citi upgraded Arcturus to ‘Buy’ and raised the price target to $20 from $8, according to The Fly.

Arcturus (ARCT) reports phase 2 ARCT-810 results lowering ammonia in OTC deficiency and plans ARCT-2601 dosing with FDA input. Read more here.

SAN DIEGO, September 23, 2026--Arcturus Therapeutics Holdings Inc. (the "Company," "Arcturus," Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory therapeutics, today announced encouraging interim Phase 2 results from ARCT-810 in ornithine transcarbamylase (OTC) deficiency and introduced LUNAR 2.0™, the Company’s next-generation mRNA delivery platform, and additional liver pipeline programs.

SAN DIEGO, August 31, 2026--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that the Company will participate in the following investor conferences:

Is it a good or bad thing when a stock experiences a golden cross technical event?

Expanding oncology and rare disease pipelines, strategic partnerships, and advances in delivery technologies are expected to drive significant market growthDublin, Aug. 26, 2026 (GLOBE NEWSWIRE) -- The "mRNA Therapeutics Market by Target Indication (Non-Small Cell Lung Cancer, Melanoma, Muscle-Invasive Urothelial Carcinoma, Propionic Acidemia, and Cystic Fibrosis) and Geographical Regions (North America, Europe, and Asia-Pacific) - Trends and Forecast, Till 2035" has been added to ResearchAndMar

The rally around MRNA names began on Wednesday after Merck and Moderna reported positive late-stage results for their personalized mRNA cancer vaccine combined with Keytruda in high-risk melanoma patients.

Detailed price information for Arcturus Therapeutics Ltd (ARCT-Q) from The Globe and Mail including charting and trades.

Detailed price information for Ceribell Inc (CBLL-Q) from The Globe and Mail including charting and trades.

Arcturus Therapeutics (NASDAQ:ARCT) is positioning its mRNA platform around two rare-disease programs targeting cystic fibrosis and ornithine transcarbamylase deficiency, while its vaccine business is intended to help support therapeutic development, President and CEO Joseph Payne said during a Cana

Detailed price information for Kodiak AI Inc (KDK-Q) from The Globe and Mail including charting and trades.

Arcturus Therapeutics: Q2 Earnings Snapshot

SAN DIEGO, August 06, 2026--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced its financial results for the quarter ended June 30, 2026, and provided corporate updates.

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

PTC Therapeutics (PTCT) delivered earnings and revenue surprises of +641.18% and +22.24%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

SAN DIEGO, July 28, 2026--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that it will release its financial results for the quarter ended June 30, 2026, after the market close on Thursday, Aug 6th and will also host a conference call and webcast at 4:30 pm Eastern Time on Aug 6, 2026.

SAN DIEGO, July 20, 2026--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that the Company will present at the following investor conference in Boston, Massachusetts:

Arcturus Therapeutics (ARCT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Thermo Fisher will provide integrated manufacturing, clinical research and commercial readiness services.